From the University of Arkansas for Medical Sciences.
Arkansas Children's Hospital, Little Rock, AR.
Pediatr Emerg Care. 2020 Jul;36(7):e387-e392. doi: 10.1097/PEC.0000000000001276.
Croup occasionally requires medical intervention for respiratory distress. Mainstays of treatment are corticosteroids and nebulized epinephrine. Diagnosis and assessment of severity remain clinical. Safety of discharge from an emergency department (ED) after treatment with corticosteroids and 1 nebulized epinephrine has been established. No evidence exists regarding risk associated with discharge after multidose nebulized epinephrine. Many patients requiring multidose nebulized epinephrine are reflexively admitted. The purpose of this study was to provide a descriptive analysis of the current management of croup, specifically patients requiring multidose nebulized epinephrine.
The Pediatric Health Information System was used to extract information on patients diagnosed with croup age 0 to 11 years, evaluated in pediatric EDs from 2004 to 2014, who received corticosteroids and at least 1 nebulized epinephrine. We retrospectively assessed patients requiring multidose nebulized epinephrine, evaluating risk of return for additional care associated with discharges and reviewing admissions for markers of disease severity.
A total of 95,403 patients were identified. Those requiring corticosteroids and multidose nebulized epinephrine (N = 8084) were less likely to return for further care if discharged from the ED (5.4% return single dose, 0.8% return multidose: P < 0.0001) and were admitted at a higher rate (10.7% admission single dose, 70.5% admission multidose: P < 0.0001). Of those admitted, only 31.7% received more than 2 treatments.
Patients requiring single-dose nebulized epinephrine are managed differently than those requiring multidose nebulized epinephrine. There is likely a role for multidose nebulized epinephrine in the outpatient management of croup. A prospective study is needed.
喉炎偶尔需要医疗干预以缓解呼吸窘迫。治疗的主要方法是皮质类固醇和雾化肾上腺素。诊断和严重程度评估仍然是临床的。在使用皮质类固醇和 1 次雾化肾上腺素治疗后,从急诊科(ED)出院是安全的。尚无关于接受多次雾化肾上腺素治疗后出院相关风险的证据。许多需要多次雾化肾上腺素的患者会被反射性收治入院。本研究的目的是对喉炎的当前治疗方法进行描述性分析,特别是需要多次雾化肾上腺素的患者。
使用儿科健康信息系统提取 2004 年至 2014 年在儿科 ED 就诊的年龄在 0 至 11 岁之间被诊断为喉炎、接受皮质类固醇和至少 1 次雾化肾上腺素治疗的患者信息。我们回顾性评估了需要多次雾化肾上腺素的患者,评估了与出院相关的再次接受治疗的风险,并审查了入院患者的疾病严重程度标志物。
共确定了 95403 名患者。如果从 ED 出院,那些需要皮质类固醇和多次雾化肾上腺素(N = 8084)的患者再次接受进一步治疗的可能性较小(单次剂量的 5.4%返回,多次剂量的 0.8%返回:P < 0.0001),并且入院率更高(单次剂量的 10.7%入院,多次剂量的 70.5%入院:P < 0.0001)。入院的患者中,只有 31.7%接受了超过 2 次治疗。
需要单次雾化肾上腺素的患者与需要多次雾化肾上腺素的患者的管理方式不同。在喉炎的门诊管理中,多次雾化肾上腺素可能有一定作用。需要进行前瞻性研究。